Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | THPO | P40225 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | EIF4E | P06730 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TOP1 | P11387 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | PNP | P00491 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7377274 | 1.00 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL3762066 | 1.00 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL12892430 | 1.00 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL6839692 | 1.00 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL13058163 | 1.00 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL24024691 | 1.00 | LMNA (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL12879146 | 0.91 | LMNA (0.54) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL24024511 | 0.91 | LMNA (0.54) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL13606971 | 0.88 | PNP (0.63) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR | |
| SCHEMBL6554011 | 0.86 | LMNA (0.46) | LMNAALDH1A1SMN1; SMN2ADORA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149538-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2015-10-06 | — | — | US | disclosed |
| US-9149538-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140288295-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-20140288295-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8778898-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2014-07-15 | — | — | US | disclosed |
| US-8778898-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130261072-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261072-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS (US) | 2013-10-03 | — | — | US | disclosed |
| US-8466276-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466276-B2 | Oligomer conjugates of heteropentacyclic nucleosides | NEKTAR THERAPEUTICS (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110039797-A1 | Oligomer Conjugates of Heteropentacyclic Nucleosides | Nektar Therapetics (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039797-A1 | Oligomer Conjugates of Heteropentacyclic Nucleosides | SLC29A2, SLC29A1, GNE | LMNA 3873/4885ALDH1A1 2313/4885SMN1; SMN2 2799/4885 |
| US-20140288295-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | SLC29A2, SLC29A1, GNE | LMNA 3873/4885ALDH1A1 2313/4885SMN1; SMN2 2799/4885 |
| US-20130261072-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | GNE, SLC29A2, ABCG2 | LMNA 3345/4885ALDH1A1 2749/4885SMN1; SMN2 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.